Neumune

Neumune (HE2100) is an injectable depot formulation of the naturally occurring steroid hormone 5-androstenediol (5-AED), developed by Hollis-Eden Pharmaceuticals as a radiation countermeasure. It was specifically designed to treat the hematopoietic components of acute radiation syndrome (ARS) by stimulating the production of white blood cells (neutrophils) and platelets, thereby addressing the life-threatening neutropenia and thrombocytopenia associated with high-dose radiation exposure. Developed in collaboration with the Armed Forces Radiobiology Research Institute (AFRRI), the drug reached Phase I clinical trials where it demonstrated the ability to increase circulating immune cells and was generally well-tolerated. However, the development program was discontinued in 2007 after the U.S. Department of Health and Human Services (HHS) declined to procure the drug for the Strategic National Stockpile, citing it as technically unacceptable for their specific requirements.

Brand names

Neumune

Other names

5-androstenediol5-AEDandrost-5-ene-3beta,17beta-diol